Inotiv appoints Terry Coelho to board, replacing Richard Johnson effective Oct 16, 2023

Inotiv, Inc.

Richard A. Johnson resigned as director; Terry Coelho appointed as Class II director.
Coelho also joins Compensation, Audit, and chairs Nominating/Corporate Governance committees.
Coelho is CFO of Gamida Cell; previously led CinCor Pharma's $190M IPO and its sale to AstraZeneca.
Director annual cash retainer $55,000; committee chairs/members receive additional retainers.
Coelho granted 12,911 restricted stock units as initial equity award.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Terry Coelho

Director

NOTV · Inotiv, Inc.

Effective: 2023-10-16
Filed: October 19, 2023, 7:59 PM ET

The Board has appointed Terry Coelho to the Board, effective October 16, 2023, to serve as a Class II director of the Company for a term ending at the Annual Meeting of Shareholders in 2026.

Departed

Richard A. Johnson

Director

NOTV · Inotiv, Inc.

Effective: 2023-10-16
Successor: Terry Coelho
Filed: October 19, 2023, 7:59 PM ET

Richard A. Johnson, Ph.D. previously tendered his resignation as a director of the Company, to be effective automatically upon notice to Dr. Johnson from the Company that the Board of Directors (the "Board") is prepared to elect an approved director as provided in the Shareholders Agreement.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Terry Coelho was appointed as Director at Inotiv, Inc..

Action: appointed
Role: Director

Exact text from the filing

The Board has appointed Terry Coelho to the Board, effective October 16, 2023, to serve as a Class II director of the Company for a term ending at the Annual Meeting of Shareholders in 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard A. Johnson resigned as Director at Inotiv, Inc..

Action: resigned
Role: Director

Exact text from the filing

Richard A. Johnson, Ph.D. previously tendered his resignation as a director of the Company, to be effective automatically upon notice to Dr. Johnson from the Company that the Board of Directors (the "Board") is prepared to elect an approved director as provided in the Shareholders Agreement.

View on SEC.gov

Inotiv, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-034692

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.